Bharat Biotech submits phase 3 clinical trial application for its booster dose of intranasal vaccine
Image Credit: institute for global change
Bharat Biotech on Monday submitted its phase 3 clinical trial application to to the Drugs Controller General of India (DCGI) for its booster dose of intranasal vaccine - BBV154, which is an intranasal replication-deficient chimpanzee adenovirus SARS-CoV-2 vectored vaccine. The development comes nearly a month after the biotech company completed Phase II trial of intranasal Covid vaccine.